NCT02389543 - Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | Biotech Hunter

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

February 28, 2018

Conditions

Multiple Myeloma

Interventions

DRUG

Selinexor

Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.

DRUG

Lenalidomide

In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).

DRUG

Dexamethasone

"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."